Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiragolumab plus atezolizumab and bevacizumab for PD-L1-positive non-squamous NSCLC
ISRCTN10010669Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tiragolumab, atezolizumab and bevacizumab in Non-small cell lung cancer (NS-NSCLC), sponsored by Roche. Primary endpoint: Objective response rate. Started Nov 2022; status: active, not recruiting.
02
Drugs
tiragolumabatezolizumabbevacizumab
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on ISRCTN10010669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN10010669.